A First-in Human, Phase I Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LY4336619, an Alkaline Phosphatase Placental-Like 2 (ALPPL2) T- Cell Engager Bispecific Antibody, in Adult Participants With Advanced Solid Tumors
Study Identifier:
J7L-MC-JUEA
CT.gov Identifier:
EudraCT Identifier:
EU Trial (CTIS) Number:
Study Contact Information:
Will Be Recruiting
Considering participating in a START clinical trial?
Study Summary
The main purpose of this study is to evaluate how safe and effective LY4336619 is in adults with advanced cancer. Some participants will receive LY4336619 alone, and some will receive it with another cancer medicine. Participants will be in the study for up to 2 years, depending on how they tolerate and respond to treatment.
Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Non-Small Cell Lung Cancer
Ovarian
Gastric
Solid Tumor
Endometrial
Testicular
Phase
The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
Phase I
Sex
Female & Male
Age
18+ years
Study Drug
Drug: EXPERIMENTAL: LY4336619 and Sofetabart Mipitecan (Sofe-M) Combination
Read More
Drug: Comparing LY4336619 in combination with Sofe-M administered IV
Drug: Drug: LY4336619
Drug: Administered IV
Drug: Drug: Sofetabart Mipitecan (Sofe-M)
Drug: EXPERIMENTAL: LY4336619 Dose Escalation
Drug: Escalating doses of LY4336619 administered intravenously (IV)
Drug: EXPERIMENTAL: LY4336619 Dose Expansion
Drug: LY4336619 administered IV
Drug: EXPERIMENTAL: LY4336619 Dose Optimization
Drug: Comparing 2 or more doses (evaluated during dose escalation) of LY4336619 administered IV
Study Status
Indicates the current recruitment status or the expanded access status
Will Be Recruiting
Requirements information
Inclusion criteria
- * Have histological diagnosis of locally advanced or metastatic solid tumor malignancy.
- * Have a life expectancy of at least 12 weeks as judged by the investigator.
- * Must be an appropriate candidate for study treatment. Study treatment is considered appropriate where approved measures are no longer effective or are not considered appropriate or safe in the opinion of the investigator, or the individual refuses the remaining most appropriate standard of care treatment.
- * Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale or Karnofsky performance status of at least 80%.
Exclusion criteria
- Has a known or suspected history of active central nervous system (CNS) involvement.
- * Has a history of carcinomatous meningitis.
- * Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease.
- * Residual symptoms of neurotoxicity from prior chimeric antigen receptor-modified T cell (CAR-T) or bispecifics.
- * Has significant cardiovascular disease
- * Has an active uncontrolled systemic bacterial, viral, fungal, or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which, in the opinion of the investigator and the sponsor, makes it undesirable for the individual to participate in the trial. Screening for chronic conditions is not required.
- * Has any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0 Grade 1 at the time of starting study treatment except for alopecia, endocrine adverse events (AEs) on replacement therapy, and Grade 2 neuropathy.
Clinical Study Information for Healthcare Providers
By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.
Study Locations
Location
Investigator
Status
Condition(s) Treated at Site
Location
START New York (Long Island)
Lake Success, NY, United States, 11042
Investigator
Geraldine O'Sullivan Coyne
Status
Will Be Recruiting
Condition(s) Treated at Site
Non-Small Cell Lung Cancer
Ovarian
Gastric
Solid Tumor
Endometrial
Testicular
Location
START Mountain Region
West Valley City, UT, United States, 84119
Investigator
William McKean
Status
Will Be Recruiting
Condition(s) Treated at Site
Non-Small Cell Lung Cancer
Ovarian
Gastric
Solid Tumor
Endometrial
Testicular